Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
File:Ampligen-response-2016.jpg
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
File
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Summary == ==== Title: (or description) ==== [[Ampligen]] (Rintatinamol) trial results summary. Figure 5. [[Compassionate use|AMP-516]] plot of ET difference from baseline in seconds at 40 weeks treatment (ordinate) per each patient (abscissa). Plot of ET difference from baseline in seconds at 40 weeks treatment (ordinate) per each patient (abscissa). Reproduced from Strayer et al. Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME): Characteristics of responders to Rintatolimod. J Drug Res Dev 2015;1: doi http://dx.doiorg/10.16966/jdrd.103.<br/> Key: ET - Exercise Tolerance test ==== Author: (or citation) ==== {{Cite journal | last =Mitchell | first = William M|author-link=William Mitchell| date = 2016-06-02 | title = Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)|url=http://www.tandfonline.com/doi/full/10.1586/17512433.2016.1172960|journal=Expert Review of Clinical Pharmacology|language=en|volume=9|issue=6|pages=755β770|doi=10.1586/17512433.2016.1172960}}<br/> Disclosure: Author William Mitchell is Chairman of the board of [[AIM ImmunoTech]], who have developed Ampligen. ==== Source: (e.g. internet address) ==== Figure 5. ==== Other information: ==== ====See also==== *[[Ampligen]] *[[Severe and very severe ME]]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
This page is a member of a hidden category:
Category:CC-BY-4.0
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs